Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Treatment with immune checkpoint inhibitors frequently leads to immune-related adverse events (irAEs). As pa...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
6 March 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27, Heft: 7, Pages: 1353-1354 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw128 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw128 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/7/1353/1741159 
|
| Verfasserangaben: | C. Bender, A. Dimitrakopoulou-Strauss, A. Enk and J.C. Hassel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1567326714 | ||
| 003 | DE-627 | ||
| 005 | 20220814061200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180118s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw128 |2 doi | |
| 035 | |a (DE-627)1567326714 | ||
| 035 | |a (DE-576)49732671X | ||
| 035 | |a (DE-599)BSZ49732671X | ||
| 035 | |a (OCoLC)1340986002 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bender, Carolin |d 1986- |e VerfasserIn |0 (DE-588)104603121X |0 (DE-627)775247642 |0 (DE-576)399340041 |4 aut | |
| 245 | 1 | 0 | |a Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment |c C. Bender, A. Dimitrakopoulou-Strauss, A. Enk and J.C. Hassel |
| 264 | 1 | |c 6 March 2016 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.01.2018 | ||
| 520 | |a © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Treatment with immune checkpoint inhibitors frequently leads to immune-related adverse events (irAEs). As patients who have previously experienced high-grade AEs with ipilimumab are excluded from most studies with anti-programmed cell death-1 or anti-programmed cell death ligand-1 antibodies (Abs), there are little data on the safety of sequential therapy in this patient population [2, 3]. However, especially BRAF wild-type melanoma patients are in need of further treatment options after progression with ipilimumab. Hence, we treated patients who had to stop ipilimumab treatment because of a severe autoimmune reaction after complete resolution of symptoms and cessation of the immunosuppressive treatment with the anti-PD-1 Ab pembrolizumab....Data from patients treated with pembrolizumab 2 mg/kg q3w was retrospectively analyzed. Eight of 49 (16.3%) patients had... | ||
| 700 | 1 | |a Enk, Alexander |d 1963- |e VerfasserIn |0 (DE-588)1032757140 |0 (DE-627)739272535 |0 (DE-576)166173517 |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 27(2016), 7, Seite 1353-1354 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g number:7 |g pages:1353-1354 |g extent:2 |a Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw128 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/27/7/1353/1741159 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180118 | ||
| 993 | |a Editorial | ||
| 994 | |a 2016 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 4 |y j | ||
| 998 | |g 1032757140 |a Enk, Alexander |m 1032757140:Enk, Alexander |d 910000 |d 911300 |e 910000PE1032757140 |e 911300PE1032757140 |k 0/910000/ |k 1/910000/911300/ |p 3 | ||
| 998 | |g 104603121X |a Bender, Carolin |m 104603121X:Bender, Carolin |d 910000 |e 910000PB104603121X |k 0/910000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1567326714 |e 2993103091 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"2 S."}],"recId":"1567326714","relHost":[{"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"title":[{"title_sort":"Annals of oncology","title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"origin":[{"dateIssuedKey":"1990","dateIssuedDisp":"1990-","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press"}],"disp":"Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatmentAnnals of oncology","physDesc":[{"extent":"Online-Ressource"}],"recId":"320428796","part":{"extent":"2","text":"27(2016), 7, Seite 1353-1354","issue":"7","pages":"1353-1354","volume":"27","year":"2016"},"id":{"zdb":["2003498-2"],"eki":["320428796"],"issn":["1569-8041"]},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"pubHistory":["1.1990 -"]}],"person":[{"given":"Carolin","role":"aut","family":"Bender","display":"Bender, Carolin"},{"display":"Enk, Alexander","role":"aut","given":"Alexander","family":"Enk"},{"family":"Hassel","role":"aut","given":"Jessica C.","display":"Hassel, Jessica C."}],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"6 March 2016"}],"note":["Gesehen am 18.01.2018"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment","title":"Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment"}],"name":{"displayForm":["C. Bender, A. Dimitrakopoulou-Strauss, A. Enk and J.C. Hassel"]},"id":{"doi":["10.1093/annonc/mdw128"],"eki":["1567326714"]}} | ||
| SRT | |a BENDERCAROSAFETYOFTH6201 | ||